Do Hyoung Lim1, Jai Hyuen Lee2, Jong Wan Kim3. 1. Division of Hematology-Oncology, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, South Korea. 2. Department of Nuclear Medicine, Dankook University College of Medicine, Cheonan, South Korea. 3. Department of Laboratory Medicine, Dankook University College of Medicine, Cheonan, South Korea.
Abstract
BACKGROUND: Colon adenoma (CA) is a premalignant lesion of colorectal cancer, and its early removal is closely associated with more prolonged survival in the general population. In this study, we aimed to evaluate the relationship between diverse biologic markers and a newly diagnosed CA and to predict the clinical possibility of cytokeratin-19 soluble in serum fragment (CYFRA 21-1) as a screening tool in asymptomatic adults aged over 45 years. METHODS: Four hundred and seventy-nine patients with a histologically confirmed CA or benign colon polyp (BCP), 76 patients with only benign colorectal diseases and 223 negative controls with no CA or BCP detected on colonofibroscopy were investigated. Multiple tumor markers and biochemical markers were simultaneously checked by radioimmunoassay and enzyme immunoassay. RESULTS: The CYFRA 21-1 alone showed significant stepwise contrastive potential among the three groups (P<.001). Based on the receiver operating characteristic (ROC) analysis, Area under the curve (AUC) for CYFRA 21-1, with a value of 0.732 (95% confidence interval, 0.656-0.809, P<.001) for differentiating between negative controls and patients with advanced colon adenoma, was comparatively the highest among all analyzed factors. The sensitivity of CYFRA 21-1 was significantly higher than that of the other tumor markers in the diagnosis of CA and advanced CA, respectively (P<.001). CONCLUSIONS: Considering the results of our study, CYFRA 21-1 showed a significant diagnostic performance and significant stepwise comparative potential in differentiating patients with CA from benign controls. CYFRA 21-1 could be a simple and effective screening test for the diagnosis of CA.
BACKGROUND:Colon adenoma (CA) is a premalignant lesion of colorectal cancer, and its early removal is closely associated with more prolonged survival in the general population. In this study, we aimed to evaluate the relationship between diverse biologic markers and a newly diagnosed CA and to predict the clinical possibility of cytokeratin-19 soluble in serum fragment (CYFRA 21-1) as a screening tool in asymptomatic adults aged over 45 years. METHODS: Four hundred and seventy-nine patients with a histologically confirmed CA or benign colon polyp (BCP), 76 patients with only benign colorectal diseases and 223 negative controls with no CA or BCP detected on colonofibroscopy were investigated. Multiple tumor markers and biochemical markers were simultaneously checked by radioimmunoassay and enzyme immunoassay. RESULTS: The CYFRA 21-1 alone showed significant stepwise contrastive potential among the three groups (P<.001). Based on the receiver operating characteristic (ROC) analysis, Area under the curve (AUC) for CYFRA 21-1, with a value of 0.732 (95% confidence interval, 0.656-0.809, P<.001) for differentiating between negative controls and patients with advanced colon adenoma, was comparatively the highest among all analyzed factors. The sensitivity of CYFRA 21-1 was significantly higher than that of the other tumor markers in the diagnosis of CA and advanced CA, respectively (P<.001). CONCLUSIONS: Considering the results of our study, CYFRA 21-1 showed a significant diagnostic performance and significant stepwise comparative potential in differentiating patients with CA from benign controls. CYFRA 21-1 could be a simple and effective screening test for the diagnosis of CA.
Authors: Clarence K W Wong; Richard N Fedorak; Connie I Prosser; Marianne E Stewart; Sander Veldhuyzen van Zanten; Daniel C Sadowski Journal: Int J Colorectal Dis Date: 2012-06-14 Impact factor: 2.571
Authors: Rafael Molina; Xavier Filella; Jose M Augé; Elvira Bosch; Aureli Torne; Jaume Pahisa; Jose A Lejarcegui; Angels Rovirosa; Begoña Mellado; Jaume Ordi; Albert Biete Journal: Anticancer Res Date: 2005 May-Jun Impact factor: 2.480
Authors: Rafael Molina; Jose M Auge; Xavier Filella; Nuria Viñolas; Julian Alicarte; Jose M Domingo; Antonio M Ballesta Journal: Anticancer Res Date: 2005 May-Jun Impact factor: 2.480
Authors: In Kyu Lee; Do Hyoung Kim; D Lee Gorden; Yoon Suk Lee; Na Young Sung; Gyeoung-Sin Park; Hyung Jin Kim; Won Kyung Kang; Jong Kyung Park; Chang Hyeok Ahn; Jun-Gi Kim; Hae Myung Jeon; Seong Taek Oh Journal: Ann Surg Oncol Date: 2009-02-03 Impact factor: 5.344
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer Journal: CA Cancer J Clin Date: 2008-03-05 Impact factor: 508.702
Authors: Jung Im Shim; Yeonju Kim; Mi Ah Han; Hoo-Yeon Lee; Kui Sun Choi; Jae Kwan Jun; Eun-Cheol Park Journal: Cancer Res Treat Date: 2010-12-31 Impact factor: 4.679